Impact of SARS-CoV-2 Pandemic on Patients with Primary Immunodeficiency

Delavari, S. and Abolhassani, H. and Abolnezhadian, F. and Babaha, F. and Iranparast, S. and Ahanchian, H. and Moazzen, N. and Nabavi, M. and Arshi, S. and Fallahpour, M. and Bemanian, M.H. and Shokri, S. and Momen, T. and Sadeghi-Shabestari, M. and Molatefi, R. and Shirkani, A. and Vosughimotlagh, A. and Safarirad, M. and Sharifzadeh, M. and Pashangzadeh, S. and Salami, F. and Shirmast, P. and Rezaei, A. and Moeini Shad, T. and Mohraz, M. and Rezaei, N. and Hammarström, L. and Yazdani, R. and Aghamohamamdi, A. (2021) Impact of SARS-CoV-2 Pandemic on Patients with Primary Immunodeficiency. Journal of Clinical Immunology, 41 (2). pp. 345-355.

Impact of SARS-CoV-2 Pandemic on Patients with Primary Immunodeficiency.pdf

Download (343kB) | Preview
Official URL:


Although it is estimated that COVID-19 life-threatening conditions may be diagnosed in less than 1:1000 infected individuals below the age of 50, but the real impact of this pandemic on pediatric patients with different types of primary immunodeficiency (PID) is not elucidated. The current prospective study on a national registry of PID patients showed that with only 1.23 folds higher incidence of infections, these patients present a 10-folds higher mortality rate compared to population mainly in patients with combined immunodeficiency and immune dysregulation. Therefore, further management modalities against COVID-19 should be considered to improve the survival rate in these two PID entities using hematopoietic stem cell transplantation and immunomodulatory agents. © 2020, The Author(s).

Item Type: Article
Additional Information: cited By 11
Uncontrolled Keywords: aciclovir; azithromycin; C reactive protein; cefixime; ceftriaxone; cotrimoxazole; dexamethasone; ethambutol; genomic DNA; hydroxychloroquine; immunoglobulin; immunomodulating agent; isoniazid; meropenem; pyridoxine; rifampicin; vancomycin, abdominal pain; Article; autoinflammatory disease; blood cell count; cardiomegaly; cellular immunity; cellular immunodeficiency; child; clinical article; cohort analysis; combined immunodeficiency; complement deficiency; computer assisted tomography; controlled study; coronavirus disease 2019; coughing; diarrhea; dyspnea; erythrocyte sedimentation rate; faintness; fatigue; female; fever; follow up; gene frequency; genetic analysis; hematopoietic stem cell transplantation; hemophagocytic syndrome; human; humoral immunity; immune deficiency; immune dysregulation; immunotherapy; infant; jaundice; loss of appetite; lymphocytopenia; male; mortality rate; oxygen saturation; pandemic; preschool child; priority journal; prospective study; respiratory distress; reverse transcription polymerase chain reaction; rhinorrhea; sequence analysis; sore throat; survival rate; tachypnea; vomiting; clinical decision making; comorbidity; complication; diagnosis; disease management; epidemiology; health impact assessment; health survey; mortality; severity of illness index; virology, Child, Preschool; Clinical Decision-Making; Comorbidity; COVID-19; Disease Management; Female; Health Impact Assessment; Humans; Infant; Male; Mortality; Primary Immunodeficiency Diseases; Public Health Surveillance; SARS-CoV-2; Severity of Illness Index
Subjects: WC Communicable Diseases
Depositing User: eprints admin
Date Deposited: 03 Aug 2021 06:47
Last Modified: 03 Aug 2021 06:47

Actions (login required)

View Item View Item